Clinical Trials Browser

Phase 2 × Lymphoma, T-Cell × pembrolizumab × Clear all

NCT03210662 2026-01-13

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

17 enrolled 9 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Phase 2 Withdrawn

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03021057 2019-04-17

Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas

Phase 2 Unknown

Lymphoma, T-Cell